Ascidian Therapeutics Raises $40 Million In Series A Extension Financing From Apple Tree Partners And Appoints Michael Ehlers As Interim Ceo
Amount Raised
$40 Million
Round Type
Series A
BostonBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, today announced $40 million in Series A extension funding committed by Apple Tree Partners (ATP). The funds will be used to advance Ascidian's lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the company's pipeline. The company also announced that its founding CEO Michael Ehlers, M.D., Ph.D., will return as interim President and Chief Executive Officer, effective immediately. Dr
Quick answer
Ascidian Therapeutics raised $40 Million in a Series A round, dated November 8, 2023. Investors: Romesh Subramanian, Ph.D., Apple Tree Partners and Ascidian. Ascidian Therapeutics is based in Boston, Massachusetts, United States.
- How much did Ascidian Therapeutics raise?
- Ascidian Therapeutics raised $40 Million in a Series A round on November 8, 2023.
- Who invested in Ascidian Therapeutics?
- Romesh Subramanian, Ph.D., Apple Tree Partners and Ascidian are named as investors in this round.
- What does Ascidian Therapeutics do?
- Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA.
- Where is Ascidian Therapeutics based and how big is it?
- Ascidian Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 34 employees.
- Who are the decision-makers at Ascidian Therapeutics?
- Fundz holds 1 contact at Ascidian Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Ascidian Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- On Target Laboratories raised $30M (Funding Round) on November 16, 2023.
- MAIA Biotechnology raised $4.9M (Seed) on November 15, 2023.
- MBrace Therapeutics raised $85M (Series B) on November 14, 2023.
- EyeBio raised an undisclosed amount (Series A) on November 14, 2023.
- Lipella Pharmaceuticals raised $3.1M (Seed) on October 23, 2023.
- Actym Therapeutics raised $60M (Series A) on October 18, 2023.
Who to call at Ascidian Therapeutics, and when
A new round usually means Ascidian Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Ascidian Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ascidian Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ascidian Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ascidian Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAscidian Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.